A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Intermittent fasting has been linked to metabolic health by improving lipid profiles, reducing body weight, and increasing insulin sensitivity. However, several randomized clinical trials have shown that intermittent fasting is not more effective than standard daily caloric restriction for short-ter...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2025.1524125/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533254142787584 |
|---|---|
| author | Aristides G. Eliopoulos Aristides G. Eliopoulos Aristides G. Eliopoulos Kalliopi K. Gkouskou Kalliopi K. Gkouskou Konstantinos Tsioufis Despina Sanoudou Despina Sanoudou Despina Sanoudou |
| author_facet | Aristides G. Eliopoulos Aristides G. Eliopoulos Aristides G. Eliopoulos Kalliopi K. Gkouskou Kalliopi K. Gkouskou Konstantinos Tsioufis Despina Sanoudou Despina Sanoudou Despina Sanoudou |
| author_sort | Aristides G. Eliopoulos |
| collection | DOAJ |
| description | Intermittent fasting has been linked to metabolic health by improving lipid profiles, reducing body weight, and increasing insulin sensitivity. However, several randomized clinical trials have shown that intermittent fasting is not more effective than standard daily caloric restriction for short-term weight loss or cardiometabolic improvements in patients with obesity. Observational studies also suggest cardiovascular benefits from extended rather than reduced eating windows, and indicate that long-term intermittent fasting regimens may increase the risk of cardiovascular disease mortality. In this perspective, we discuss evidence that may support potential adverse effects of intermittent fasting on cardiovascular health through the loss of lean mass, circadian misalignment and poor dietary choices associated with reward-based eating. Given the ongoing revolution in obesity pharmacotherapy, we argue that future research should integrate anti-obesity medications with dietary strategies that confer robust benefits to cardiometabolic health, combine exercise regimens, and consider genetic factors to personalize obesity treatment. Comprehensive approaches combining diet, pharmacotherapy, and lifestyle modifications will become crucial for managing obesity and minimizing long-term cardiovascular risk. |
| format | Article |
| id | doaj-art-a9aba3c1e790447dbff54072fa93a8d5 |
| institution | Kabale University |
| issn | 2296-861X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj-art-a9aba3c1e790447dbff54072fa93a8d52025-01-17T05:10:23ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2025-01-011210.3389/fnut.2025.15241251524125A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapyAristides G. Eliopoulos0Aristides G. Eliopoulos1Aristides G. Eliopoulos2Kalliopi K. Gkouskou3Kalliopi K. Gkouskou4Konstantinos Tsioufis5Despina Sanoudou6Despina Sanoudou7Despina Sanoudou8Department of Biology, Medical School, National and Kapodistrian University of Athens, Athens, GreeceCenter for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GreeceGenosophy S.A., National and Kapodistrian University of Athens Spin-off Company, Athens, GreeceDepartment of Biology, Medical School, National and Kapodistrian University of Athens, Athens, GreeceGenosophy S.A., National and Kapodistrian University of Athens Spin-off Company, Athens, Greece1st Department of Cardiology, Hippokration Hospital of Athens, National and Kapodistrian University of Athens, Athens, GreeceCenter for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GreeceClinical Genomics and Pharmacogenomics Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GreeceBiomedical Research Foundation of the Academy of Athens, Athens, GreeceIntermittent fasting has been linked to metabolic health by improving lipid profiles, reducing body weight, and increasing insulin sensitivity. However, several randomized clinical trials have shown that intermittent fasting is not more effective than standard daily caloric restriction for short-term weight loss or cardiometabolic improvements in patients with obesity. Observational studies also suggest cardiovascular benefits from extended rather than reduced eating windows, and indicate that long-term intermittent fasting regimens may increase the risk of cardiovascular disease mortality. In this perspective, we discuss evidence that may support potential adverse effects of intermittent fasting on cardiovascular health through the loss of lean mass, circadian misalignment and poor dietary choices associated with reward-based eating. Given the ongoing revolution in obesity pharmacotherapy, we argue that future research should integrate anti-obesity medications with dietary strategies that confer robust benefits to cardiometabolic health, combine exercise regimens, and consider genetic factors to personalize obesity treatment. Comprehensive approaches combining diet, pharmacotherapy, and lifestyle modifications will become crucial for managing obesity and minimizing long-term cardiovascular risk.https://www.frontiersin.org/articles/10.3389/fnut.2025.1524125/fullintermittent fastingprecision medicineanti-obesity pharmacotherapycardiovascular diseasegeneticsGLP-1 |
| spellingShingle | Aristides G. Eliopoulos Aristides G. Eliopoulos Aristides G. Eliopoulos Kalliopi K. Gkouskou Kalliopi K. Gkouskou Konstantinos Tsioufis Despina Sanoudou Despina Sanoudou Despina Sanoudou A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy Frontiers in Nutrition intermittent fasting precision medicine anti-obesity pharmacotherapy cardiovascular disease genetics GLP-1 |
| title | A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| title_full | A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| title_fullStr | A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| title_full_unstemmed | A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| title_short | A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| title_sort | perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy |
| topic | intermittent fasting precision medicine anti-obesity pharmacotherapy cardiovascular disease genetics GLP-1 |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2025.1524125/full |
| work_keys_str_mv | AT aristidesgeliopoulos aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT aristidesgeliopoulos aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT aristidesgeliopoulos aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT kalliopikgkouskou aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT kalliopikgkouskou aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT konstantinostsioufis aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou aperspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT aristidesgeliopoulos perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT aristidesgeliopoulos perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT aristidesgeliopoulos perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT kalliopikgkouskou perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT kalliopikgkouskou perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT konstantinostsioufis perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy AT despinasanoudou perspectiveonintermittentfastingandcardiovascularriskintheeraofobesitypharmacotherapy |